Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). The 2-year OS rate was 54.1% vs 37.2%, an improvement of 16.9%; with a median...
Covered in this story
Call it yourself
No calls on $III yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Information Services Group Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.